The Role of Metabolic Syndrome in the Development and Progression of Chronic Renal Failure
Article Sidebar
Main Article Content
Abstract
The metabolic syndrome has become an increasing health problem in the world, both, in developing and in developed countries. It is well known that the metabolic syndrome components (obesity, hypertension, hyperlipidemia and insulin resistance) increases the incidence and therefore the morbidity and mortality caused by cardiovascular diseases. There are studies that also suggest the association between the metabolic syndrome and the development and progression of chronic renal disease. The correlation between the single entities of the metabolic syndrome such as hypertension and insulin resistance in the development of chronic renal failure is well known, but there are still dilemmas and discussions about the effect of the complete metabolic syndrome in the renal function impairment. The possible renal function damaging mechanisms includes insulin resistance, oxidative stress, microvascular damage and ischemia of the kidneys.
The aim of this article is to systematize the data collected from studies that suggest association of these two pathological conditions, to better understanding how the components of the metabolic syndrome affect the progression of chronic renal disease, the reduction in the glomerular filtration rate and the renal patophysiological changes.
The present article comprises recent information and findings and their application in the treatment of metabolic syndrome associated with CKD including reduction of body weight, lifestyle change with a modified diet and adequate physical activity.Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
References
Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37:1595–1607. DOI: https://doi.org/10.2337/diabetes.37.12.1595
Kaplan NM. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med. 1989;149(7):1514-20. DOI: https://doi.org/10.1001/archinte.149.7.1514
Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143–3421. DOI: https://doi.org/10.1161/circ.106.25.3143
Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant C. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109:433–438. DOI: https://doi.org/10.1161/01.CIR.0000111245.75752.C6
Alberti KG, Zimmet P, Shaw J. The metabolic syndrome--a new worldwide definition. Lancet. 2005;366:1059–1062. DOI: https://doi.org/10.1016/S0140-6736(05)67402-8
World Health Organisation. Energy and protein requirements. Report of a joint FAO/WHO/UNU expert consultation. Geneva, Switzerland: World Health Organisation;. WHO Technical Report Series, 1985: 724.
Obunai K, Jani S, Dangas GD. Cardiovascular morbidity and mortality of the metabolic syndrome. Med Clin North Am. 2007;91(6):1169–1184. DOI: https://doi.org/10.1016/j.mcna.2007.06.003
Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care. 2005;28:1769–1778. DOI: https://doi.org/10.2337/diacare.28.7.1769
Resnick HE, Jones K, Ruotolo G, Jain AK, Henderson J, Lu W, Howard BV. Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease in nondiabetic american indians: the Strong Heart Study. Diabetes Care. 2003;26:861–867. DOI: https://doi.org/10.2337/diacare.26.3.861
Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K, Omatsu T, Nakajima T, Sarui H, Shimazaki M, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med. 2005;143:722–728. DOI: https://doi.org/10.7326/0003-4819-143-10-200511150-00009
Lin WY, Liu CS, Li TC, Lin T, Chen W, Chen CC, Li CI, Lin CC. In addition to insulin resistance and obesity, hyperuricemia is strongly associated with metabolic syndrome using different definitions in Chinese populations: a population-based study (Taichung Community Health Study) Ann Rheum Dis. 2008;67:432–433. DOI: https://doi.org/10.1136/ard.2007.073601
Ford ES. Prevalence of the metabolic syndrome defied by the International Diabetes Federation among adults in the US Diabetes Care. 2005;28:2745-2749. DOI: https://doi.org/10.2337/diacare.28.11.2745
Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287(3):356–359. DOI: https://doi.org/10.1001/jama.287.3.356
Nashar K, Egan BM. Relationship between chronic kidney disease and metabolic syndrome: current perspectives. Diabetes Metab Syndr Obes. 2014; 7:421-35. DOI: https://doi.org/10.2147/DMSO.S45183
Ervin RB. Prevalence of metabolic syndrome among adults 20 years of age and over, by sex, age, race and ethnicity, and body mass index: United States, 2003–2006. Natl Health Stat Report. 2009;13: 1–7.
Kidney Disease: Improving Gobal Outcomes (KDIGO) CKD Work Group KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Supp. 2013;3(1):1–150.
Kurella M, Lo JC, Chertow GM.: Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol. 2005;16: 2134–2140. DOI: https://doi.org/10.1681/ASN.2005010106
Brown WW, Peters RM, Ohmit SE, et al. Early detection of kidney disease in community settings: the Kidney Early Evaluation Program (KEEP). American Journal of Kidney Diseases.2003;42(1):22–35. DOI: https://doi.org/10.1016/S0272-6386(03)00405-0
Gelber RP, Kurth T, Kausz AT, et al. Association between body mass index and CKD in apparently healthy men. American Journal of Kidney Diseases. 2005;46(5):871–880. DOI: https://doi.org/10.1053/j.ajkd.2005.08.015
Kramer H, Luke A, Bidani A, Cao G, Cooper R, McGee D. Obesity and prevalent and incident CKD: the Hypertension Detection and Follow-Up Program. American Journal of Kidney Diseases. 2005;46(4):587–594. DOI: https://doi.org/10.1053/j.ajkd.2005.06.007
Stengel B, Tarver-Carr ME, Powe NR, Eberhardt MS, Brancati FL. Lifestyle factors, obesity and the risk of chronic kidney disease. Epidemiology. 2003;14(4):479–487. DOI: https://doi.org/10.1097/01.EDE.0000071413.55296.c4
Rasouli N, Kern PA. Adipocytokines and the Metabolic Complications of Obesity. The Journal of Clinical Endocrinology and Metabolism. 2008;93(11 Suppl 1):S64-S73. DOI: https://doi.org/10.1210/jc.2008-1613
Chiu HK, Tsai EC, Juneja R, Stoever J, Brooks-Worrell B, Goel A, Palmer JP. Equivalent insulin resistance in latent autoimmune diabetes in adults (LADA) and type 2 diabetic patients. Diabetes Res Clin Pract. 2007;77(2):237-44. DOI: https://doi.org/10.1016/j.diabres.2006.12.013
Reaven GM. Role of Insulin Resistance in Human Disease. Diabetes. 1988;37:12 1595-1607. DOI: https://doi.org/10.2337/diab.37.12.1595
Qu H-Q, Li Q, Rentfro AR, Fisher-Hoch SP, McCormick JB. The Definition of Insulin Resistance Using HOMA-IR for Americans of Mexican Descent Using Machine Learning. PLoS ONE. 2011;6(6):e21041. DOI: https://doi.org/10.1371/journal.pone.0021041
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412-9. DOI: https://doi.org/10.1007/BF00280883
Landin K, Krotkiewski M, Smith U. Importance of obesity for the metabolic abnormalities associated with an abdominal fat distribution. Metabolism. 1989;38:572-576. DOI: https://doi.org/10.1016/0026-0495(89)90219-9
Després JP1, Tremblay A, Pérusse L, Leblanc C, Bouchard C. Abdominal adipose tissue and serum HDL-cholesterol: association independent from obesity and serum triglyceride concentration. Int J Obes. 1988;12(1):1-13.
Hoehner CM, Greenlund KJ, Rith-Najarian S, Casper ML, McClellan WM. Association of the insulin resistance syndrome and microalbuminuria among nondiabetic native Americans. The Inter-Tribal Heart Project. J Am Soc Nephrol. 2002;13(6):1626–1634. DOI: https://doi.org/10.1097/01.ASN.0000015762.92814.85
Chen J, Muntner P, Hamm LL, et al. Insulin resistance and risk of chronic kidney disease in nondiabetic US adults. J Am Soc Nephrol. 2003;14(2):469–477. DOI: https://doi.org/10.1097/01.ASN.0000046029.53933.09
Li Y, Xie D, Qin X, Tang G, Xing H, Li Z, Xu X, Xu X, Hou F. Metabolic syndrome, but not insulin resistance, is associated with an increased risk of renal function decline. Clin Nutr. 2015;34(2):269-75. DOI: https://doi.org/10.1016/j.clnu.2014.04.002
Hager SR. Insulin resistance of uremia. Am J Kidney Dis. 1989;14(4):272–276. DOI: https://doi.org/10.1016/S0272-6386(89)80201-X
DeFronzo RA, Alvestrand A, Smith D, Hendler R, Hendler E, Wahren J. Insulin resistance in uremia. J Clin Invest. 1981;67(2):563–568. DOI: https://doi.org/10.1172/JCI110067
Kobayashi S, Maesato K, Moriya H, Ohtake T, Ikeda T. Insulin resistance in patients with chronic kidney disease. Am J Kidney Dis. 2005;45(2):275–280. DOI: https://doi.org/10.1053/j.ajkd.2004.09.034
Kershaw EE, Flier JS. Adipose Tissue as an Endocrine Organ. J Clin Endocrinol Metab. 2004; 89(6):2548–2556. DOI: https://doi.org/10.1210/jc.2004-0395
Nitta K. Possible link between metabolic syndrome and chronic kidney disease in the development of cardiovascular cisease. Cardiol Res Pract. 2011;2011:963517. DOI: https://doi.org/10.4061/2011/963517
Wolf G, Chen S, Han DC, Ziyadeh FN. Leptin and renal disease. Am J Kidney Dis. 2002;39(1):1–11. DOI: https://doi.org/10.1053/ajkd.2002.29865
Williams KW, Scott MM, Elmquist JK. From observation to experimentation: leptin action in the mediobasal hypothalamus. Am J Clin Nutr. 2009;89(3):985S-990S. DOI: https://doi.org/10.3945/ajcn.2008.26788D
Weigle DS, Duell PB, Connor WE, Steiner RA, Soules MR, Kuijper JL. Effect of fasting, refeeding, and dietary fat restriction on plasma leptin levels. J. Clin. Endocrinol. Metab. 1997;82(2): 561–5. DOI: https://doi.org/10.1210/jc.82.2.561
Margetic S, Gazzola C, Pegg GG, Hill RA. Leptin: a review of its peripheral actions and interactions. Int. J. Obes. Relat. Metab. Disord. 2002;26(11): 1407–1433. DOI: https://doi.org/10.1038/sj.ijo.0802142
Kim HJ, Vaziri ND, Norris K, An WS, Quiroz Y, Rodriguez-Iturbe B. High-calorie diet with moderate protein restriction prevents cachexia and ameliorates oxidative stress, inflammation and proteinuria in experimental chronic kidney disease. Clin Exp Nephrol. 2010;14(6):536–547. DOI: https://doi.org/10.1007/s10157-010-0340-x
Abou-Youssef H, Kholoussi S, Ishak M, Kholoussi N, Zahraa Ahmed El. Estimation of resistin in chronic kidney disease. Archive of Hellenic Medicine: ISSN 1105-3992
Cawthorn WP, Scheller EL, Learman BS, Parlee SD, Simon BR, Mori H, Ning X, Bree AJ, Schell B, Broome DT, Soliman SS, DelProposto JL, Lumeng CN, Mitra A, Pandit SV, Gallagher KA, Miller JD, Krishnan V, Hui SK, Bredella MA, Fazeli PK, Klibanski A, Horowitz MC, Rosen CJ, MacDougald OA. Bone marrow adipose tissue is an endocrine organ that contributes to increased circulating adiponectin during caloric restriction. Cell Metab. 2014;20(2):368-75. DOI: https://doi.org/10.1016/j.cmet.2014.06.003
Scheller EL, Rosen CJ. What's the matter with MAT? Marrow adipose tissue, metabolism, and skeletal health. Annals of the New York Academy of Sciences. 2014;1311(1):14-30. DOI: https://doi.org/10.1111/nyas.12327
Renaldi O, Pramono B, Sinorita H, Purnomo LB, Asdie RH, Asdie AH. Hypoadiponectinemia: a risk factor for metabolic syndrome. Acta Med Indones. 2009;41(1): 20–4.
Becker B, Kronenberg F, Kielstein JT, et al. MMKD Study Group Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study. J Am Soc Nephrol. 2005;16(4):1091–1098. DOI: https://doi.org/10.1681/ASN.2004090742
Zoccali C, Mallamaci F, Tripepi G, et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol. 2002;13(1):134–141. DOI: https://doi.org/10.1681/ASN.V131134
Manrique C, Lastra G, Gardner M, Sowers JR. The renin angiotensin aldosterone system in hypertension: roles of insulin resistance and oxidative stress. Med Clin North Am. 2009;93(3):569–582. DOI: https://doi.org/10.1016/j.mcna.2009.02.014
Rashidi A, Ghanbarian A, Azizi F. Are patients who have metabolic syndrome without diabetes at risk for developing chronic kidney disease? Evidence based on data from a large cohort screening population. Clin J Am Soc Nephrol. 2007;2(5):976–983. DOI: https://doi.org/10.2215/CJN.01020207
Wang C, Blough ER, Arvapalli R, et al. Metabolic syndrome-induced tubulointerstitial injury: role of oxidative stress and preventive effects of acetaminophen. Free Radic Biol Med. 2013;65:1417–1426. DOI: https://doi.org/10.1016/j.freeradbiomed.2013.10.005
Hallan S, de Mutsert R, Carlsen S, Dekker FW, Aasarí¸d K, Holmen J. Obesity, smoking, and physical inactivity as risk factors for CKD: are men more vulnerable? Am J Kidney Dis. 2006;47(3):396–405. DOI: https://doi.org/10.1053/j.ajkd.2005.11.027
Finkelstein J, Joshi A, Hise MK. Association of physical activity and renal function in subjects with and without metabolic syndrome: a review of the Third National Health and Nutrition Examination Survey (NHANES III) Am J Kidney Dis. 2006;48(3):372–382. DOI: https://doi.org/10.1053/j.ajkd.2006.05.013
Hsu CY, McCulloch CE, Iribarren C, Darbinian J, Go AS. Body mass index and risk for end-stage renal disease. Ann Intern Med. 2006;144(1):21–28. DOI: https://doi.org/10.7326/0003-4819-144-1-200601030-00006
54. Bolignano D1, Zoccali C. Effects of weight loss on renal function in obese CKD patients: a systematic review. Nephrol Dial Transplant. 2013 Nov;28 Suppl 4:iv82-98. DOI: https://doi.org/10.1093/ndt/gft302
Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int. 2001;59(1):260–269. DOI: https://doi.org/10.1046/j.1523-1755.2001.00487.x
Tonelli M, Wanner C. Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members Lipid management in chronic kidney disease: synopsis of the Kidney Disease: Improving Global Outcomes 2013 clinical practice guideline. Ann Intern Med. 2014;160(3):182. DOI: https://doi.org/10.7326/M13-2453
Kitiyakara C, Yamwong S, Cheepudomwit S, et al. The metabolic syndrome and chronic kidney disease in a Southeast Asian cohort. Kidney Int. 2007;71(7):693–700. DOI: https://doi.org/10.1038/sj.ki.5002128
Thomas G, Sehgal AR, Kashyap SR, Srinivas TR, Kirwan JP, Navaneethan SD. Metabolic syndrome and kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2011;6(10):2364–2373. DOI: https://doi.org/10.2215/CJN.02180311
Lea JP, Greene EL, Nicholas SB, Agodoa L, Norris KC. Cardiorenal metabolic syndrome in the African diaspora: rationale for including chronic kidney disease in the metabolic syndrome definition. Ethn Dis. 2009;19(2 Suppl 2):S2–S11.
Gluba A, Mikhailidis DP, Lip GY, Hannam S, Rysz J, Banach M. Metabolic syndrome and renal disease. Int J Cardiol. 2013;164(2):141–150. DOI: https://doi.org/10.1016/j.ijcard.2012.01.013
Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific Statement. Circulation. 2005;112(17):2735–2752. DOI: https://doi.org/10.1161/CIRCULATIONAHA.105.169404